Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom's macroglobulinemia, and mantle-cell lymphoma

Journal of Clinical Oncology

Volumn 17, Issue 2, 1999, Pages 546-553

  Foran, James M ^a   Rohatiner, Ama Z S ^a   Coiffier, Bertrand ^a   Barbui, Tiziano ^a   Johnson, Stephen A ^a   Hiddemann, Wolfgang ^a   Radford, John A ^a   Norton, Andrew J ^a   Tollerfield, Susan M ^a   Wilson, Martin P ^a   Lister, T Andrew ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; FLUDARABINE PHOSPHATE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MANTLE CELL LYMPHOMA; MUCOSA INFLAMMATION; PANCYTOPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; TREATMENT INDICATION; WALDENSTROEM MACROGLOBULINEMIA;

EID: 0032976375     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.2.546     Document Type: Article

References (43)

1. Galton DAG, Israels LG, Nabarro JDN, et al: Clinical trial of p (di-chloroethylamino) phenylbutyric acid (CB 1348) in malignant lymphoma. BMJ 2:1172, 1955
2. Brittinger G, Bartels H, Common H, et al: Clinical and prognostic relevance of the Kiel classification of non-Hodgkin's lymphomas: Results of a prospective multicenter study by the Kiel Lymphoma Study Group. Hematol Oncol 2:269-306, 1984
3. Richards MA, Hall PA, Gregory WM, et al: Lymphoplasmacytoid and small cell centrocytic non-Hodgkin's lymphoma: A retrospective analysis from St. Bartholomew's Hospital 1972-1986. Hematol Oncol 7:19-35, 1989
4. Papamichael D, Rohatiner AZS, Mulatero C, et al: Lymphoplasmacytoid lymphoma: A retrospective analysis from St. Bartholomew's Hospital 1972-96. Proc Am Soc Clin Oncol 16:17A, 1997 (abstr 57)
5. Dimopoulos MA, Alexanian R: Waldenstrom's macroglobulinemia. Blood 83:1452-1459, 1994
6. Norton AJ, Matthews J, Pappa V, et al: Mantle cell lymphoma: Natural history defined in a serially biopsied population over a 20 year period. Ann Oncol 6:249-256, 1995
7. Gallagher CJ, Gregory WM, Jones AE, et al: Follicular lymphoma: Prognostic factors for response and survival. J Clin Oncol 4:1470-1480, 1986
8. DeVita VT, Canellos GP, Chabner B, et al: Advanced diffuse histiocytic lymphoma, a potentially curable disease. Lancet 1:248, 1975
9. Fisher RI, Gaynor ER, Dahlberg S, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006, 1993
10. Lister TA, Cullen MH, Beard MEJ, et al: Comparison of combined and single-agent chemotherapy in non-Hodgkin's lymphoma of favorable histological sub-type. BMJ 1:533-537, 1978
11. Dana BW, Dahlberg S, Nathwani BN, et al: Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol 11:644-651, 1993
12. Adkins JC, Peters DH, Markham A: Fludarabine: An update of its pharmacology and use in the treatment of haematological malignancies. Drugs 53:1005-1037, 1997
13. Warrell RP, Berman E: Phase I and II study of fludarabine phosphate in leukemia: Therapeutic efficacy with delayed central nervous system toxicity. J Clin Oncol 4:74-79, 1986
14. Keating MJ, Kantarjian H, Talpaz M, et al: Fludarabine: A new agent with major activity against chronic lymphocytic leukemia. Blood 74:19-25, 1989
15. Hochster HS, Kim K, Green MD, et al: Activity of fludarabine in previously-treated non-Hodgkin's low-grade lymphoma: Results of an Eastern Cooperative Oncology Group study. J Clin Oncol 10:28-32, 1992
16. Hiddemann W, Unterhalt M, Pott C, et al: Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin's lymphoma: A phase II study of the German low-grade non-Hodgkin's lymphoma study group. Semin Oncol 20:28-31, 1993 (suppl 7)
17. Pigaditou A, Rohatiner AZS, Whelan JS, et al: Fludarabine in low-grade lymphoma. Semin Oncol 20:24-27, 1993 (suppl 7)
18. Zinzani PL, Lauria F, Rondelli D, et al: Fludarabine: An active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma. Ann Oncol 4:575-578, 1993
19. Solal-Celigny P, Brice P, Brousse N, et al: Phase II trial of fludarabine monophosphate as first-line therapy in patients with advanced follicular lymphoma: A multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 14:514-519, 1996
20. Stansfeld AG, Diebold J, Noel H, et al: Updated Kiel classification for lymphomas. Lancet 1:292-293, 1988 (letter)
21. Berger F, Felman P, Sonet A, et al: Nonfollicular small B-cell lymphomas: An heterogeneous group of patients with distinct clinical features and outcome. Blood 83:2829-2835, 1994
22. Harris NL, Jaffe ES, Stein H, et al: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994
23. Harris NL, Bhan AK: B cell neoplasms of the lymphocytic, lymphoplasmacytoid and plasma cell types: Immunohistologic analysis and clinical correlation. Hum Pathol 16:829-837, 1985
24. Shivdasani R, Hess JL, Skarin AT, et al: Intermediate lymphocytic lymphoma: Clinical and pathologic features of a recently characterized subtype of non-Hodgkin's lymphoma. J Clin Oncol 11:802-811, 1993
25. Kaplan ES, Meier P, Non-parametric estimation from incomplete observation. Am Stat Assoc J 53:457-480, 1958
26. Dimopoulos MA, Kantarjian H, Weber D, et al: Primary therapy of Waldenstrom's macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol 12:2694-2698, 1994
27. Dhodapkar M, Jacobson J, Gertz M, et al: Phase II intergroup trial of fludarabine in Waldenstrom's macroglobulinemia: Results of a South Western Oncology Group trial 9003 in 220 patients. Proc Am Soc Hem 90:577a, 1997 (abstr)
28. Meusers P, Engelhard M, Bartels H, et al: Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: Anthracycline does not improve the prognosis. Hematol Oncol 7:365-380, 1989
29. Hiddemann W, Brittinger G, Tiemann M, et al: Clinical characteristics and response to chemotherapy of mantle cell lymphomas: Results of a European survey. Proc Am Soc Hem 88:674a, 1996 (abstr)
30. Decaudin D, Bosq J, Tertian G, et al: Phase II trial of fludarabine monophosphate in patients with mantle cell lymphoma. J Clin Oncol 16:579-583, 1998
31. Dimopoulos MA, O'Brien S, Kantarjian H, et al: Fludarabine therapy of Waldenstrom's macroglobulinemia. Am J Med 95:49-52, 1993
32. Johnson PWM, Fearnley J, Domizio P, et al: Neurological illness following treatment with fludarabine. Br J Cancer 70:966-968, 1994
33. Cheson BD, Vena DA, Foss FM, et al: Neurotoxicity of purine analogs: A review. J Clin Oncol 12:2216-2228, 1994
34. Orchard JA, Bolam S, Oscier DG: Association of myelodysplastic changes with purine analogues. Br J Haematol 100:677-679, 1998
35. Ketterer N, Salles G, Dumontet C, et al: Fludarabine may increase the toxicity of peripheral blood progenitor cell transplantation. Proceedings of the Internatial Society of Hematology-European Hematology Association Combined Congress, Amsterdam, the Netherlands, July 4-8, 1998. Br J Haematol 102:204a, 1998 (abstr)
36. McLaughlin P, Hagemeister FB, Swan F Jr, et al: Phase I study of fludarabine, mitoxantrone and dexamethasone in low-grade lymphoma. J Clin Oncol 12:575-579, 1994
37. McLaughlin P, Hagemeister FB, Romaguera JE, et al: Fludarabine, mitoxantrone and dexamethasone: An effective new regimen for indolent lymphoma. J Clin Oncol 1262-1268, 1996
38. Zinzani PL, Bendandi M, Tura S: FMP regimen (fludarabine, mitoxantrone, prednisone) as therapy in recurrent low-grade non-Hodgkin's lymphoma. Eur J Haematol 55:262-266, 1995
39. Klasa R, Connors J, Gascoyne R, et al: CPF (cyclophosphamide, prednisone, fludarabine) in advanced stage previously untreated low-grade and mantle cell lymphoma. Proc Am Soc Hem 90:342a, 1997 (abstr)
40. Hochster H, Oken M, Bennett J, et al: Efficacy of cyclophosphamide and fludarabine as first line therapy of low-grade non-Hodgkin's lymphoma-ECOG 1491. Proc Am Soc Hem 84:383a, 1994 (abstr)
41. Zinzani PL, Bendandi M, Magagnoli M, et al: Fludarabine-mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin's lymphoma. Ann Oncol 8:379-383, 1997
42. Pott C, Unterhalt M, Sandford D, et al: Fludarabine as single agent and in combination with mitoxantrone and dexamethasone in relapsed and refractory low-grade non-Hodgkin's lymphoma. Ann Haematol 68:A2, 1994 (suppl 1)
43. McLaughlin P, Cabanillas F, Younes A, et al: Stage IV low-grade lymphoma: Randomized trial of two innovative regimens, with monitoring of Bcl-2 by PCR. Proceedings of the VI Internatioal Conference on Malignant Lymphoma. Ann Oncol 7:A109, 1996 (suppl 3)